BR112018015444A2 - inaladores de pó seco - Google Patents

inaladores de pó seco

Info

Publication number
BR112018015444A2
BR112018015444A2 BR112018015444A BR112018015444A BR112018015444A2 BR 112018015444 A2 BR112018015444 A2 BR 112018015444A2 BR 112018015444 A BR112018015444 A BR 112018015444A BR 112018015444 A BR112018015444 A BR 112018015444A BR 112018015444 A2 BR112018015444 A2 BR 112018015444A2
Authority
BR
Brazil
Prior art keywords
dry powder
local
powder inhalers
diseases
inhalers
Prior art date
Application number
BR112018015444A
Other languages
English (en)
Other versions
BR112018015444B1 (pt
Inventor
Adamo Benoit
Laurenzi Brendan
C Smutney Chad
Guarneri Joseph
P Kinsey Spencer
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of BR112018015444A2 publication Critical patent/BR112018015444A2/pt
Publication of BR112018015444B1 publication Critical patent/BR112018015444B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/10—General characteristics of the apparatus with powered movement mechanisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
    • A61M2205/121—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit interface between cassette and base
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
    • A61M2205/128—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/14—Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production

Abstract

trata-se de um inalador de pó seco que inclui cartuchos substituíveis que contêm um pó seco para distribuição local ou sistêmica através do trato pulmonar e pulmões. os inaladores são usados com pós secos inaláveis, incluindo formulações de medicamento que compreendem agentes ativos para distribuição local ou sistêmica e para o tratamento de doenças, tais como hipertensão pulmonar, doença cardiovascular, anafilaxia, diabetes, obesidade, câncer e outras doenças ou sintomas associados a essas e outras doenças, tais como náusea, vômito, dor e inflamação.
BR112018015444-0A 2016-01-29 2017-01-27 Inalador de pó seco BR112018015444B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289095P 2016-01-29 2016-01-29
US62/289,095 2016-01-29
PCT/US2017/015486 WO2017132601A1 (en) 2016-01-29 2017-01-27 Dry powder inhaler

Publications (2)

Publication Number Publication Date
BR112018015444A2 true BR112018015444A2 (pt) 2018-12-18
BR112018015444B1 BR112018015444B1 (pt) 2023-12-19

Family

ID=59386335

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018015444-0A BR112018015444B1 (pt) 2016-01-29 2017-01-27 Inalador de pó seco

Country Status (12)

Country Link
US (4) US20170216538A1 (pt)
EP (2) EP3407870B1 (pt)
JP (3) JP2019504684A (pt)
CN (2) CN108778249B (pt)
AU (2) AU2017211410B2 (pt)
BR (1) BR112018015444B1 (pt)
CA (2) CA3199504A1 (pt)
HK (1) HK1258955A1 (pt)
IL (1) IL260823B1 (pt)
MX (2) MX2018009159A (pt)
SG (1) SG11201806304PA (pt)
WO (1) WO2017132601A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
EP1928423B1 (en) 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA2982550C (en) 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
CN105451716A (zh) 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2015200049A1 (en) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
USD824015S1 (en) * 2016-01-29 2018-07-24 Mannkind Corporation Inhaler
USD841798S1 (en) * 2016-01-29 2019-02-26 Mannkind Corporation Inhaler
USD824016S1 (en) * 2016-01-29 2018-07-24 Mannkind Corporation Inhaler
USD824510S1 (en) * 2016-01-29 2018-07-31 Mannkind Corporation Inhaler
CA3023257A1 (en) * 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
US20180271826A1 (en) * 2017-03-22 2018-09-27 Colorado Can Llc Dry powders of cannabinoids and methods for preparing dry powders
USD834178S1 (en) * 2017-05-19 2018-11-20 Mannkind Corporation Inhaler
EP3641864A1 (en) * 2017-06-23 2020-04-29 Københavns Universitet Inhaler with acoustic flow monitoring
USD851748S1 (en) * 2017-11-08 2019-06-18 Mannkind Corporation Inhaler
US20210069106A1 (en) * 2018-01-26 2021-03-11 Novartis Ag High dose delivery of inhaled therapeutics
EP3801552A4 (en) * 2018-06-07 2022-02-23 MannKind Corporation COMPOSITION AND METHOD OF INHALATION
CA3133804A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders
USD898187S1 (en) * 2019-05-21 2020-10-06 Receptor Holdings, Inc. Inhaler device
EP4041208A4 (en) * 2019-09-18 2023-07-19 Board of Regents, The University of Texas System CANNABINOID COMPOSITIONS FOR ADMINISTRATION BY INHALATION
CA3171220A1 (en) * 2020-03-19 2021-09-23 Glenn MATTES Dried particle inhalation for delivery of cannabis
EP4167979A1 (en) * 2020-06-19 2023-04-26 Cannovex BV Pulmonary formulation comprising cannabinoids
CN115089825A (zh) * 2022-07-06 2022-09-23 苏州易合医药有限公司 肺部给药装置
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
EP1082108B1 (en) * 1997-12-03 2002-12-18 Britannia Pharmaceuticals Limited Improvements in medicaments for asthma treatment
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
CA2483914A1 (en) * 2002-05-07 2003-11-20 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
WO2004054647A1 (en) * 2002-12-13 2004-07-01 Otsuka Pharmaceutical Co., Ltd. Inhalation device for transpulmonary administration
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
CA2551127A1 (en) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Treatment of breakthrough pain by drug aerosol inhalation
US7452524B2 (en) * 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
DE102004006450B4 (de) * 2004-02-05 2012-09-27 Ing. Erich Pfeiffer Gmbh Dosiervorrichtung
WO2006014930A2 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
BRPI0514263B8 (pt) 2004-08-20 2021-05-25 Mannkind Corp método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
KR101306384B1 (ko) * 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
WO2006111169A1 (en) * 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
EP1928423B1 (en) * 2005-09-14 2015-12-09 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
JP2009519972A (ja) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド 粒子ベースの経肺投与または経鼻投与用製薬の製造方法
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
US20080078382A1 (en) * 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
WO2008049000A2 (en) * 2006-10-18 2008-04-24 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
WO2009055742A2 (en) * 2007-10-24 2009-04-30 Mannkind Corporation Delivery of active agents
WO2009152160A1 (en) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
CA2982550C (en) 2008-06-13 2020-08-25 Mannkind Corporation A dry powder inhaler and system for drug delivery
EP2330893A4 (en) * 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
CA2755514C (en) 2009-03-18 2018-03-13 Mannkind Corporation Inhaler adaptor for a laser diffraction apparatus and method for measuring particle size distribution
MX2011013313A (es) * 2009-06-12 2012-01-25 Mannkind Corp Microparticulas de dicetopiperazina con contenidos de isomero definidos.
ES2943333T3 (es) 2009-06-12 2023-06-12 Mannkind Corp Micropartículas de dicetopiperazina con superficies específicas definidas
RU2553881C2 (ru) * 2009-11-02 2015-06-20 Мэннкайнд Корпорэйшн Реактор и способ производства частиц в процессе осаждения
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) * 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CA2812417C (en) * 2010-09-29 2019-10-22 Pulmatrix, Inc. Cationic dry powders
KR101915241B1 (ko) * 2010-09-29 2018-11-06 풀매트릭스 오퍼레이팅 컴퍼니, 인크 흡입용의 1가 금속 양이온 건조 분말
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
CN109999013A (zh) * 2012-02-29 2019-07-12 普马特里克斯营业公司 可吸入干粉剂
JP2015526523A (ja) * 2012-08-29 2015-09-10 マンカインド コーポレイション 高血糖症の治療のための方法および組成物
WO2014100231A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
KR102391750B1 (ko) * 2013-03-15 2022-04-28 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
CN105451716A (zh) * 2013-07-18 2016-03-30 曼金德公司 热稳定性干粉药物组合物和方法
CA2938244A1 (en) * 2014-02-07 2015-08-13 Auspex Pharamaceuticals, Inc. Novel pharmaceutical formulations
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
US10328216B2 (en) * 2016-01-20 2019-06-25 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispensible spray dried powders suitable for inhalation
US20210085897A1 (en) * 2018-04-06 2021-03-25 Lupin Inc. Medicament dispenser

Also Published As

Publication number Publication date
EP3407870A1 (en) 2018-12-05
IL260823B1 (en) 2024-04-01
EP3407870B1 (en) 2022-06-29
MX2018009159A (es) 2019-06-13
JP2019504684A (ja) 2019-02-21
AU2017211410B2 (en) 2022-10-13
AU2022224822A1 (en) 2022-09-29
AU2017211410A1 (en) 2018-08-09
EP4079291A1 (en) 2022-10-26
CN108778249A (zh) 2018-11-09
IL260823A (pt) 2024-04-01
HK1258955A1 (zh) 2019-11-22
MX2023001592A (es) 2023-03-15
US20210146071A1 (en) 2021-05-20
CA3012679A1 (en) 2017-08-03
CA3199504A1 (en) 2017-08-03
CN108778249B (zh) 2022-05-27
BR112018015444B1 (pt) 2023-12-19
US20170216538A1 (en) 2017-08-03
WO2017132601A1 (en) 2017-08-03
US20230098083A1 (en) 2023-03-30
SG11201806304PA (en) 2018-08-30
EP3407870A4 (en) 2019-07-31
US20200046917A1 (en) 2020-02-13
JP2022160697A (ja) 2022-10-19
JP2023154079A (ja) 2023-10-18
CA3012679C (en) 2023-12-12
CN114904100A (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
BR112018015444A2 (pt) inaladores de pó seco
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
MX371521B (es) Sistema de inhalacion de polvo seco.
CY1115499T1 (el) Συσκευη εισπνοων
BR112013007371A2 (pt) inalador.
MX2015000538A (es) Sistemas y metodos de suministro de farmaco en polvo seco.
JP2007520506A5 (pt)
WO2005084638A3 (en) Formulations decreasing infectivity of pulmonary diseases
BR112019005168A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica
CL2017001859A1 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
CY1117758T1 (el) Κουμπι επιστομιου εισπνευστηρα ξηρας κονεως
NI201400139A (es) Nueva forma de dosificación y formulación de abediterol
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
EA201201395A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
BR112015018121A2 (pt) composição para terapia por inalação, composição farmacêutica, inalador de pó seco, inalador pressurizado dosimetrado ou inalador nasal ativado por respiração, método de tratar uma doença ou distúrbio respiratório ou uma doença ou distúrbio pulmonar em um paciente, e, método de preparar composições ou inaladores
MX2017013950A (es) Polvos de zolmitriptán para suministro pulmonar.
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
MX2021011491A (es) Polvos secos inhalables.
TR201002877A2 (tr) Blister ambalaj içeren inhalasyon cihazı
EA201201394A1 (ru) Ингалятор для доставки лекарственного средства в виде сухого порошка
TR201712424A2 (tr) Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
Jeong Inhalation therapy in respiratory diseases
BR112021024979A2 (pt) Formulações à base de carreador e métodos relacionados
Shakhnazarova et al. Current possibilities of nebulizer therapy in the treatment of respiratory pathology in children

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: MANNKIND CORPORATION (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/01/2017, OBSERVADAS AS CONDICOES LEGAIS